FDA

Latest Stories
The realignment comes at a critical time in the animal drug review program, the agency reports.
The “Paws, Claws, Hooves, Fins, and Feet—Advancements through a One Health Approach” virtual One Health symposium is set for Nov. 19, 2024. RACE credits are available.
The agency has developed an online Q&A to answer questions about veterinarians’ federal requirements with regard to these topic areas.
Data from NARMS are used by FDA in the regulatory review of new animal antimicrobial drugs, and to develop policies on judicious antimicrobial use in animals.
“ACTPs have the potential to make significant changes in how we treat diseases and may provide novel therapies for unmet therapeutic needs of animals,” reports Dr. Janet Woodcock, Acting Commissioner of the FDA.
Parasites are becoming increasingly resistant to drugs that were generally effective against them in the past.
Expanded conditional approval has the potential to incentivize drug development and provide veterinarians with legally marketed new animal drugs.
Research needed to help define duration of use for certain medically important antimicrobial drugs for food animals.
On November 21, 2019, at 1:00-2:30 p.m. EST, the FDA’s Center for Veterinary Medicine will hold a public webinar about the agency’s newly-released draft Guidance for Industry #256.
Performance measures track the progress of the Center of Veterinary Medicine’s (CVM) Five-Year Plan for Supporting Antimicrobial Stewardship in Veterinary Settings.